Steglatro (ertugliflozin) / Pfizer, Merck (MSD) - LARVOL DELTA

Ertugliflozin Reduces Blood Pressure and EGFR during Both Moderate- and High-Sodium Intake in People with Type 2 Diabetes. (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • EGFR

Ertugliflozin Mitigates Blood Pressure Increments during a High-Sodium Diet in People with Type 2 Diabetes (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SGLT-2 INHIBITOR USE IS ASSOCIATED WITH REDUCED RISK OF ATRIAL FIBRILLATION IN HFPEF WITHOUT DIABETES (ACC 2026) - "New SGLT2i users without diabetes (empagliflozin, dapagliflozin, canagliflozin, or ertugliflozin) were compared with matched HFpEF controls without diabetes or SGLT2i exposure. In a large real-world HFpEF cohort without diabetes, SGLT2i initiation was associated with a 16% lower risk of both incident AF and HF hospitalization at 24 months. These findings support an anti-arrhythmic benefit of SGLT2i independent of glycemic effects and highlight the value of early SGLT2i initiation in HFpEF even in the absence of diabetes."

Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders

Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review. (PubMed, Pulmonology) - "RIF co-administration with gemigliptin, evogliptin and canagliflozin requires caution and potential requiring dose adjustments, while saxagliptin, dapagliflozin, ertugliflozin and empagliflozin appear safer alternatives. The limited inclusion of DM patients with TB, restricted to one study with latent TB infection, further reduces generalisability. We developed a clinical decision algorithm to support co-treatment in TB - DM cases, but further dedicated studies are warranted to guide optimal co-treatment."

Journal • PK/PD data • Review • Diabetes • Hematological Disorders • Infectious Disease • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Do SGLT2 Inhibitors Influence Parkinson's Disease Risk? A Meta-analysis of Randomized Trials (AAN 2026) - "No eligible data were found for ertugliflozin, enavogliflozin, henagliflozin, ipragliflozin, luseogliflozin, or tofogliflozin...Subgroup analyses showed no significant effect for individual agents: empagliflozin 10 mg (OR 0.64, 95% CI 0.17–2.43), empagliflozin 25 mg (OR 0.33, 95% CI 0.01–8.15), dapagliflozin 10 mg (OR 0.33, 95% CI 0.09–1.23), sotagliflozin (OR 0.25, 95% CI 0.03–2.24), canagliflozin 100 mg (OR 3.00, 95% CI 0.31–28.81), and bexagliflozin (OR 1.50, 95% CI 0.06–36.99)... SGLT2 inhibitors do not significantly alter the risk of PD. These findings support their neurological safety, though longer follow-up and dedicated neurodegenerative outcome trials are warranted."

Retrospective data • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Movement Disorders • Nephrology • Parkinson's Disease • Renal Disease • Type 2 Diabetes Mellitus

Explore the potential mechanisms between ertugliflozin and kidney cancer through bioinformatics analysis and Mendelian randomization study. (PubMed, Int J Surg) - "Ertugliflozin may affect kidney cancer by targeting ESR2. SGLT2 inhibition may also be a contributing factor to renal cancer, and further investigation is required."

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Placental transfer characteristics and functional impact of SGLT2 inhibitors in human experimental models. (PubMed, Biomed Pharmacother) - "We investigated placental transfer mechanisms of dapagliflozin (DAPA), empagliflozin (EMPA), ertugliflozin (ERTU) and canagliflozin (CANA) using term placentas and complementary in vitro assays. Our findings indicate that at clinically relevant concentrations, SGLT2i cross the placenta by passive diffusion, modulated by efflux transporters and protein binding, and might alter placental glycolytic activity without impairing viability, differentiation, or hormone secretion. Their use during pregnancy should remain contraindicated, but if attempted, monitoring unbound drug concentrations is advised."

Journal • Diabetes • Metabolic Disorders

Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population. (PubMed, Diabet Med) - "Ertugliflozin was associated with a higher risk of DKA relative to comparators. HRs were higher among new users with no-concomitant insulin use than those with concomitant insulin use. Results were consistent with prior SGLT2i data and highlighted the importance of caution by both patients and physicians."

Journal • Medicare • Reimbursement • US reimbursement • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Treatment with ertugliflozin mitigates the hyperinsulinemic response to intra-articular triamcinolone acetonide. (PubMed, Equine Vet J) - "Treatment with ertugliflozin decreases glucose and insulin changes following IA corticosteroid administration in metabolically normal horses. Further investigation of this treatment strategy in insulin dysregulated horses is warranted as it may reduce hyperinsulinemia and, therefore, the risk of laminitis with IA corticosteroid administration."

Journal

Comparison of the efficacy of antidiabetic agents in type 2 diabetes with MASLD: a network meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "Ertugliflozin was the most effective in reducing ALT and AST levels, followed by pioglitazone and metformin for ALT, and pioglitazone and ipragliflozin for AST. Ertugliflozin may be the most effective option for improving liver function and metabolic parameters in patients with MASLD and T2DM. Further studies are needed to confirm these findings."

Clinical • Journal • Retrospective data • Review • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Bioinformatics study of the pharmacological mechanism of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus and coronary heart disease based on network pharmacology. (PubMed, Medicine (Baltimore)) - "Molecular docking results showed that ertugliflozin had the strongest intermolecular binding to EGFR and that ertugliflozin improved the viability of high-glucose (HG)/high-lipid combined hypoxia-reoxygenation-injured (HG/HP + H/R) cardiomyocytes and inhibited EGFR expression in cardiomyocytes...Molecular docking and cell experiments further confirmed that SGLT2i-ERTU improves HG/HP + H/R myocardial cell injury by targeting EGFR. Our study deepened the pharmacological mechanism of SGLT2is in the treatment of T2DM combined with CHD and provided a new perspective and therapeutic basis for future experimental research and healthcare."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Heart Failure • Metabolic Disorders • Oncology • Reperfusion Injury • Type 2 Diabetes Mellitus • EGFR

Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus. (PubMed, J Pharm Bioallied Sci) - "They were randomly given either empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Bexagliflozin, Sotagliflozin (an SGLT2 inhibitor) or liraglutide, Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin (n GLP-1 receptor agonist) to consume for 24 weeks. But GLP-1 agonists are better at helping people lose weight and keep their hearts healthy, so they are also a fantastic choice for people who have these problems. It's crucial to consider what each patient needs and what could go wrong while establishing treatment plans for them."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Cureus) - "This benefit was consistent across most agents, including empagliflozin, canagliflozin, dapagliflozin, and sotagliflozin, while ertugliflozin showed a nonsignificant trend in the same direction. The results demonstrate that SGLT2 inhibitors confer clinically meaningful cardiorenal protection that is recognized to occur through mechanisms largely independent of glucose lowering, reinforcing their role as cornerstone agents in the management of T2DM. These findings highlight the importance of prioritizing SGLT2 inhibitors in contemporary diabetes care to reduce the global burden of heart failure (HF)."

Journal • Retrospective data • Review • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Impact of Ertugliflozin on Cardiac Structure and Function in Patients with ICDs/CRT-Ds Assessed by Echocardiography: A Post Hoc Sub-Analysis of the ERASe Trial. (PubMed, J Clin Med) - "Lower LVEF at baseline was associated with a higher number of ventricular arrhythmias in both treatment groups. In this sub-analysis of the ERASe trial, treatment with ertugliflozin did not improve structural and functional parameters assessed by echocardiography after 52 weeks of treatment compared to placebo despite the significant reduction in arrhythmic burden."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

Multiscale computational analysis reveals enhanced allosteric modulation of Nav1.5 by dual binding of dapagliflozin and ertugliflozin. (PubMed, Sci Rep) - No abstract available

Journal • NAV1

Attenuation of cerebral ischemia-reperfusion induced neurotoxicity by telmisartan, ertugliflozin, and omaveloxolone through Nrf2/HO-1 pathway modulation: In vivo and in silico insights. (PubMed, Toxicol Rep) - "In silico analysis revealed strong binding through highly negative docking scores of telmisartan and ertugliflozin to Nrf2 negative regulators Keap1 and GSK-3β, supported by stable molecular dynamics simulations, suggesting direct inhibition. In conclusion, omaveloxolone, telmisartan, and ertugliflozin alleviate ischemia-reperfusion induced neurotoxicity via potential Nrf2-mediated antioxidant and anti-inflammatory mechanisms, highlighting their potential preventive role in conditions predisposing to stroke."

Journal • Preclinical • Cardiovascular • CNS Disorders • Diabetes • Hypertension • Metabolic Disorders • Oncology • Reperfusion Injury • Vascular Neurology • HMOX1 • IL6 • KEAP1 • MMP9 • TNFA

Ultrasensitive, green molecularly-imprinted poly(o-phenylenediamine) sensor on pencil graphite for trace ertugliflozin quantification in plasma and tablets. (PubMed, BMC Chem) - "The environmental impact of the proposed method was assessed using the AGREE and GAPI green evaluation tools, which confirmed its environmentally friendly nature. Furthermore, the sensor exhibited high selectivity in the presence of commonly co-formulated drugs, such as sitagliptin and metformin, indicating its potential for pharmaceutical applications."

Journal

Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Dementia Risk in Type 2 Diabetes: A Comprehensive Bayesian Network Meta-Analysis (AHA 2025) - "For all-cause dementia versus control according to the SUCRA: albiglutide (RR: 0.03, 95% CrI: 0.00 to 0.08; SUCRA: 94.4%), lixisenatide (RR: 0.08, 95% CrI: 0.00 to 0.20; SUCRA: 93.62%), efpeglenatide (RR: 0.24, 95% CrI: 0.00 to 1.38; SUCRA: 70.09%), canagliflozin (RR: 0.31, 95% CrI: 0.01 to 1.47; SUCRA: 61.81%), semaglutide (RR: 0.50, 95% CrI: 0.03 to 1.98; SUCRA: 50.06%), liraglutide (RR: 2.12, 95% CrI: 0.02 to 9.89; SUCRA: 41.91%), empagliflozin (RR: 0.68, 95% CrI: 0.05 to 2.35; SUCRA: 39.63%), exenatide (RR: 4.13, 95% CrI: 0.02 to 20.28; SUCRA: 35.41%), dulaglutide (RR: 3.38, 95% CrI: 0.03 to 15.72; SUCRA: 32.89%), dapagliflozin (RR: 1.19, 95% CrI: 0.09 to 4.96; SUCRA: 30.37%), ertugliflozin (RR: 6.79, 95% CrI: 0.02 to 29.23; SUCRA: 30.1%), control (SUCRA: 19.67%). GLP-1RAs and SGLT2is reduce dementia risk, with albiglutide and lixisenatide excelling for all-cause dementia, dapagliflozin and ertugliflozin for vascular dementia, and dulaglutide for Alzheimer's...."

Retrospective data • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SGLT2 Inhibitors in LVAD Patients: A Multi-Center Propensity-Matched Cohort Analysis (AHA 2025) - "Patients were stratified based on exposure to SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) post-implant. In this large real-world analysis, SGLT2 inhibitor use in LVAD patients was associated with markedly reduced 1-year mortality and improved cardiorenal and infectious outcomes. These findings suggest a potential role for SGLT2i in optimizing medical therapy in LVAD recipients, a population not included in pivotal HF trials. This retrospective analysis may be affected by residual confounding despite rigorous matching."

Clinical • Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Heart Failure • Infectious Disease • Nephrology • Renal Disease

Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: An updated drug/dose-dependent meta-analysis. (PubMed, Clin Nephrol) - "SGLT2 inhibitors confer renal protection in both diabetic and non-diabetic populations, supporting their use in CKD management across a broad spectrum of patients. However, careful drug selection is warranted in diabetic patients at risk for DKA."

Journal • Retrospective data • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease

The Relationship between Sodium-Glucose Co-Transporter 2 Inhibitors and Erythrocytosis: A Retrospective Review from a Large Urban Center (ASH 2024) - "The most popular SGLT-2 inhibitor was empagliflozin (79.4%) followed by dapagliflozin (8.8%), ertugliflozin (8.8%), and canagliflozin ( 3%). Given the considerable benefit of SGLT2i, further studies could focus on long-term patient monitoring, as the benefits of continuing SGLT2i may outweigh the risks of discontinuation. Additionally, further education should be provided to primary care providers regarding the possibility of erythrocytosis while on SGLT2i to prevent unnecessary workup, especially if the time to peak Hb/HCT levels is around two years, as our study showed."

Retrospective data • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hematological Disorders • Metabolic Disorders • Nephrology • Obstructive Sleep Apnea • Renal Disease • Respiratory Diseases • Sleep Disorder • Venous Thromboembolism • JAK2

A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of Fecal Microbiota Capsule Transplantation Combined with Henagliflozin in Patients with Type 2 Diabetic Kidney Disease (ChiCTR) - P=N/A | N=100 | Not yet recruiting | Sponsor: Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Southwest Medical University

New trial • Diabetes • Diabetic Nephropathy • Nephrology • Renal Disease • Transplantation • Type 2 Diabetes Mellitus

Association of SGLT2 Inhibitors with Reduced Mortality and Improved Clinical Outcomes in Patients with Cancer and CKD: A Real-World Propensity-Matched Analysis (KIDNEY WEEK 2025) - "Patients prescribed SGLT2i (dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, sotagliflozin) were matched 1:1 to controls without SGLT2i. Conclusion SGLT2i use in cancer patients with CKD is associated with substantial reductions in mortality and major adverse renal, cardiovascular, and healthcare utilization outcomes, but is linked to a higher hazard of DKA. These findings support SGLT2i therapy as a promising strategy in this vulnerable population, with appropriate DKA risk monitoring."

Clinical • Clinical data • Real-world • Real-world evidence • Acute Kidney Injury • Anemia • Chronic Kidney Disease • Congestive Heart Failure • Diabetic Nephropathy • Fatigue • Heart Failure • Metabolic Disorders • Myocardial Infarction • Nephrology • Oncology • Renal Disease

Impact of SGLT2 Inhibitor Use on Cardiac Allograft Vasculopathy and Other Clinical Outcomes in Heart Transplant Recipients: A Propensity-Matched Real-World Study (AHA 2025) - "Exposure was defined as initiation of SGLT2i therapy within 5 years after transplant (canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin). In this multicenter real-world cohort of heart transplant recipients, SGLT2 inhibitor use was associated with significantly reduced all-cause mortality, rejection and hospitalization, without an increase in transplant rejection. There was no significant increase in CAV. These findings support the potential role of SGLT2i as a safe adjunct in selected post-transplant patients."

Clinical • Clinical data • Real-world • Real-world evidence • Cardiovascular • Immunology • Transplant Rejection • Transplantation

Comparative Risk of Acute Pancreatitis in Hypertriglyceridemia Patients Treated With SGLT2 Inhibitors vs GLP-1 Receptor Agonists: A Propensity-Score Matched Analysis (ACG 2025) - "In propensity-score–matched cohorts of 22,042 patients per arm, the incidence of acutepancreatitis was higher in patients treated with SGLT2 inhibitors compared to GLP-1receptor agonists, acute pancreatitis occurred in 0.349% of the SGLT2 users versus0.263% of the GLP-1 RA(OR 1.33, 95% CI 0.95–1.87; P = 0.10).In a multivariable Cox regression analysis adjusting for individual medications, For SGLT2inhibitors, the adjusted hazard ratios were: canagliflozin (aHR < 0.0001, 95% CI 0–0; P =0.9844), dapagliflozin (aHR 1.22, 95% CI 0.45–3.28; P = 0.6982), empagliflozin (aHR 0.77, 95%CI 0.34–1.73; P = 0.5249), and ertugliflozin (aHR < 0.0001, 95% CI 0–0; P = 0.9954). ForGLP-1 receptor agonists, results included: albiglutide (aHR < 0.0001, 95% CI 0–0; P = 0.9962),dulaglutide (aHR 1.19, 95% CI 0.63–2.25; P = 0.5968), semaglutide (aHR 1.58, 95% CI0.81–3.10; P = 0.1808), liraglutide (aHR 0.59, 95% CI 0.24–1.45; P = 0.2501), and exenatide(aHR 0.30, 95% CI 0.04–2.17; P =..."

Clinical • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Pancreatitis